Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biovaxys Technology Corp
(OP:
BVAXF
)
0.0546
+0.0008 (+1.49%)
Streaming Delayed Price
Updated: 9:50 AM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,000
Open
0.0538
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0538
Today's Range
0.0546 - 0.0546
52wk Range
0.0091 - 0.0758
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 01, 2022
Vancouver, BC – December 1, 2022 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run...
Via
FinancialNewsMedia
Performance
YTD
+41.45%
+41.45%
1 Month
-8.70%
-8.70%
3 Month
+76.13%
+76.13%
6 Month
+405.56%
+405.56%
1 Year
+88.28%
+88.28%
More News
Read More
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Via
FinancialNewsMedia
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 06, 2022
Via
FinancialNewsMedia
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
May 18, 2022
Via
FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
Via
FinancialNewsMedia
Exposures
COVID-19
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
BIOVAXYS ANNOUNCES MAJOR RESEARCH COLLABORATION WITH THE OHIO STATE UNIVERSITY TO DEVELOP BROADLY REACTIVE PAN-SARBECOVIRUS VACCINE
December 07, 2021
Via
FinancialNewsMedia
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
November 09, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
COVID-19
Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
November 09, 2021
Via
FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
October 20, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
October 20, 2021
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
October 20, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
October 06, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
September 28, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
September 28, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
BIOVAXYS BEGINS TOXICITY STUDY AHEAD OF COVIDTH IND SUBMISSION
September 28, 2021
Via
FinancialNewsMedia
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
September 23, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
September 23, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
BIOVAXYS PREPARES FOR GROUND-BREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS
September 23, 2021
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.